Meningococcal And Pneumococcal Conjugate Vaccine And Method Of Using Same

Abstract

This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both S. pneumoniae and N. meningitides in a subject. In a preferred aspect, the immunogenic composition comprises covalently conjugated recombinant PsaA (“rPsaA”) from S. pneumoniae and capsular polysaccharide from N. meningitidis serogroup C. This disclosure further relates to methods for producing the immunogenic composition as well as methods for their use.

What is claimed is: 
     
         1 . A vaccine comprising capsular polysaccharide from  N. meningitidis  conjugated to a pneumococcal protein. 
     
     
         2 . The vaccine of  claim 1  wherein the  N. meningitidis  capsular polysaccharide is derived from at least one  N. meningitidis  serogroup selected from the group consisting of serogroups A, B, C, D, X, Y, Z, 29E, W-135, and combinations thereof. 
     
     
         3 . The vaccine of  claim 2  wherein the  N. meningitidis  capsular polysaccharide is derived from  N. meningitidis  serogroup C. 
     
     
         4 . The vaccine of  claim 1  wherein the pneumococcal protein is selected from the group consisting of PsaA, pneumolysin, PspA, PspC, CbpA, pneumococcal histidine triad protein selected from the group consisting of PhtA, BVH11-3, PhtB, PhpA, BVH-11, PhtE, BVH-3, PhtD and BVH-11-2, PcpA, PppA, Dpr, NanA, NanB, PiuA, PiaA, LytA, LytB, LytC, ClpP, PavA, and combinations thereof. 
     
     
         5 . The vaccine of  claim 4  wherein the pneumococcal protein is PsaA. 
     
     
         6 . A method for generating an immune response against  N. meningitidis  and  S. pneumoniae  in an individual, the method comprising administering to the individual an amount of vaccine composition effective for generating an immune response to both  N. meningitidis  and  S. pneumoniae , wherein the vaccine composition comprises  N. meningitidis  capsular polysaccharide conjugated to a pneumococcal protein. 
     
     
         7 . The method of  claim 6  wherein the vaccine is administered by a route selected from the group consisting of oral intravenous, intramuscular , nasal, subcutaneous, intraperitoneal, and combinations thereof. 
     
     
         8 . The method of  claim 6  wherein the  N. meningitidis  capsular polysaccharide is derived from at least one  N. meningitidis  serogroup selected from the group consisting of serogroups A, B, C, D, X, Y, Z, 29E, W-135, and combinations thereof. 
     
     
         9 . The method of  claim 8  wherein the  N. meningitidis  polysaccharide is derived from  N. meningitidis  serogroup C. 
     
     
         10 . The method of  claim 6  wherein the pneumococcal protein is selected from the group consisting of of PsaA, pneumolysin, PspA, PspC, CbpA, pneumococcal histidine triad protein selected from the group consisting of PhtA, BVH11-3, PhtB, PhpA, BVH-11, PhtE, BVH-3, PhtD and BVH-11-2, PcpA, PppA, Dpr, NanA, NanB, PiuA, PiaA, LytA, LytB, LytC, ClpP, PavA, and combinations thereof. 
     
     
         11 . The method of  claim 10  wherein the pneumococcal protein is PsaA.